Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
0 [1 A6 D2 }. j5 j+ Y* hNOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
& Y, T- w2 m! ~- C! }. D; W- h' r+ Author Affiliations H; x o+ T( ~: F6 P& B: J) z$ n
! s5 Q- ~# Z. P" X( G1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
( j c' s- x5 [ q% _2 q2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan ( S/ P4 J+ ?% N+ ]0 g8 u
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
, a* ^# v: m( [% g4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
1 D+ I/ Z7 O8 C6 B! ? q+ P% ~) h5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan # u& D) B. O* y( j! S
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
9 g4 J) h( m6 u9 U1 K7Kinki University School of Medicine, Osaka 589-8511, Japan
" K- t: I, t" r& e/ h8Izumi Municipal Hospital, Osaka 594-0071, Japan 8 r% D; a, I" A% j
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
& _( R7 Y+ X: yCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp + T* h7 H; @9 _9 Y4 Z( }! a
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. # z0 ^$ ?% w6 ^1 a: b! k. s
, A3 G" {' r+ H8 u8 V |